West Pharmaceutical Services (WST) News
NYSE: WSTHealth CareMedical/Dental InstrumentsUSD
366.00+2.73 (+0.75%)
At close: Oct 9, 4:02 PM ET · Delayed 15 min
WST news summary
We found 19 recent headlines mentioning West Pharmaceutical Services (WST): 8 in the past week and 12 in the past 30 days, most often from Nasdaq, PR Newswire. For price context, WST is up 0.75% at $366.00. The most recent story, "Reasons to Hold Veeva Systems Stock in Your Portfolio for Now", was published by Nasdaq on Oct 9, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest West Pharmaceutical Services headlines
- Reasons to Hold Veeva Systems Stock in Your Portfolio for NowVEEV's strong second-quarter results, Vault CRM migrations and AI expansion support growth, while market saturation remains a key concern.NasdaqVEEV, WST, GMED, VCYT
- Here's Why You Should Retain WAT Stock in Your Portfolio for NowWaters' growth outlook is fueled by strong analytical sciences demand, BD synergies and innovation, even as China weakness and integration risks persist.NasdaqWAT, WST, OPK, GMED
- West to Host Third-Quarter 2026 Conference CallEXTON, Pa., Oct. 8, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will…PR Newswire
- BDX Expands U.S. Manufacturing With $19B Healthcare InvestmentBD plans a $19B U.S. investment, including $3B for manufacturing, to boost domestic medical consumables capacity and supply-chain resilience.NasdaqBDX, WST, OPK, GMED
- Veeva's DQS Scales Data Automation Across 1,000+ Clinical StudiesVEEV's DQS cleans clinical trial data for over 1 million subjects across 1,000+ studies, expanding automation in clinical data management.NasdaqVEEV, WST, GMED, VCYT
- Reasons to Retain Cardinal Health Stock in Your Portfolio for NowCAH enters fiscal 2027 with Pharma profit growth, emerging growth engines and efficiency gains offsetting revenue headwinds.NasdaqCAH, MMSI, WST, GMED
- Veeva's OpenData to Help Servier Build a Global AI Data FoundationVEEV's OpenData deal with Servier across 80+ countries strengthens its Data Cloud role as life sciences firms scale AI and advanced analytics.NasdaqVEEV, WST, GMED, VCYT
- Inspire Medical Gains New CPT Codes for Hypoglossal Nerve StimulationINSP gains new Category I CPT codes for Inspire V procedures, creating a dedicated coding framework effective Jan. 1, 2028.NasdaqINSP, ISRG, WST, GMED
- Here's Why You Should Retain BDX Stock in Your Portfolio for NowBecton, Dickinson's MedTech transformation, innovation pipeline and strategic partnerships support growth despite reimbursement and macroeconomic pressures.NasdaqBDX, WST, GMED, VCYT
- Veeva Unveils AI Study Builder Agent to Speed Clinical Trial SetupVEEV's AI-powered Study Builder Agent automates clinical study setup, cutting manual work while strengthening its connected Clinical Data ecosystem.NasdaqVEEV, WST, GMED, VCYT
- Veeva Unveils Falcon Router to Streamline Biopharma Case RoutingVEEV launches Falcon Router to automate biopharma case routing, deepening AI integration across regulated life sciences workflows.NasdaqVEEV, WST, GMED, VCYT
- BDX Deploys Vmax 160 to Advance Intelligent Pharmacy AutomationBD expands U.S. pharmacy automation with Vmax 160 at Fairview to handle complex specialty and refrigerated medications.NasdaqBDX, WST, GMED, VCYT
- Here's Why You Should Retain Ecolab Stock in Your Portfolio NowECL benefits from high-tech growth, digital expansion, innovation and solid Q2 results, while cost fluctuations remain a key concern.NasdaqECL, WST, GMED, VCYT
- Here's Why You Should Retain Cencora Stock in Your Portfolio for NowCencora's specialty momentum, OneOncology growth and GLP-1 volumes offer upside, but drug-price cuts and MWI risks cloud its outlook.NasdaqCOR, WST, GMED, VCYT
- Cencora Launches Cell and Gene Therapy Enablement for Health SystemsCOR launches CGT Enablement to help health systems build and scale cell and gene therapy programs with financial, operational and access support.NasdaqCOR, WST, GMED, VCYT
- Natera & Angiex Partner to Evaluate AGX101 Response With SignateraNTRA teams with Angiex to use Signatera in a Phase 1 AGX101 trial, aiming to track ctDNA and deepen insights into treatment response.NasdaqNTRA, WST, GMED, VCYT
- BDX Completes PREVENT Trial Enrollment for Phasix Mesh StudyBD concludes PREVENT trial enrollment, advancing Phasix Mesh toward a potential FDA submission for incisional hernia prevention.NasdaqBDX, COO, WST, GMED
- WST Stock Surges 38.1% Since March-End: What's Fueling the Rally?West Pharmaceutical Services has surged 38.1% since March-end as HVP demand, GLP-1 growth and productivity gains fuel the rally.NasdaqWST, BDX, BAX, ATR
- WST Gains 15.3% in Three Months as HVP Growth Strengthens OutlookWST's HVP growth, wider margins and raised 2026 outlook support its recent rally, but a premium valuation raises the bar for further gains.NasdaqWST, BDX, ATR